Estrogen receptors (ERs) regulate multiple complex physiological processes in humans.
Abnormal ER signaling may result in various disorders, including reproductive system …

Rapid advance in oncology leads to increasing survival of oncologic patients. More and
more of them live long enough to reach either the natural age of menopause or, as a side …

Abstract Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized
care in melanoma and other cancers; however, therapeutic resistance is common and …

Immune checkpoint blockade (ICB) therapies have significantly prolonged patient survival
across multiple tumor types, particularly in melanoma. Interestingly, sex-specific differences …

Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with
some differences related to ethnicity and age and, above all, sex and gender. Differences …

Importance Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment
and are now standard of care. Although sex is associated with immune function and immune …

In the last three decades cutaneous melanoma has been widely investigated as a steroid
hormone-sensitive cancer. Following this hypothesis, many epidemiological studies have …

Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in
20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer …

Metastases constitute the greatest causes of deaths from cancer. However, no effective
therapeutic options currently exist for cancer patients with metastasis. Estrogen receptor β …

The association between use of menopausal hormone therapy (HT) and occurrence of skin
malignant melanoma (SMM) is controversial. We investigated the issue in a nationwide …